Core Viewpoint - The company intends to increase the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and maximize shareholder returns while ensuring the safety of the raised funds and the implementation of investment projects [1][5][7]. Summary by Sections Fundraising Basic Situation - The company was approved for its initial public offering (IPO) on November 27, 2020, with a total of 48.676088 million shares issued at a price of RMB 43.22 per share, raising a total of RMB 2,103.7805 million. After deducting issuance costs, the net amount raised was RMB 1,942.3216 million [1]. Fund Investment Project Basic Situation - The total planned investment for the projects funded by the raised capital is RMB 1,355.8911 million, with the same amount allocated for fundraising [2]. Previous Use of Idle Funds for Cash Management - The company previously approved the use of up to RMB 880 million of temporarily idle funds for cash management, allowing for the purchase of safe, liquid financial products. This approval is valid for 12 months from the board's decision [2][3]. Current Increase in Cash Management Usage - The company plans to increase the cash management limit by RMB 60 million, bringing the total to RMB 940 million. This increase is also valid for 12 months from the board's approval [4][6]. Investment Purpose - The aim is to rationally utilize temporarily idle funds for cash management to improve fund efficiency and increase returns for shareholders, without affecting the implementation of investment projects [3][5]. Investment Products - The company will invest in high-safety, principal-protected, and liquid products, including but not limited to guaranteed financial products, structured deposits, large certificates of deposit, and time deposits [4]. Implementation and Disclosure - The company’s chairman is authorized to make investment decisions within the approved limits, and the finance department will organize the implementation. The company will comply with relevant disclosure obligations [4][5]. Impact on the Company - The increase in cash management usage will not affect the normal operation of the company’s funds or the implementation of investment projects, and it is expected to generate additional investment returns for the company and its shareholders [5][7]. Review Procedures and Opinions - The board and supervisory committee have approved the increase in cash management usage, confirming that it aligns with legal requirements and does not harm the interests of the company or minority shareholders [6][7].
之江生物: 国泰海通证券股份有限公司关于上海之江生物科技股份有限公司增加使用部分暂时闲置募集资金进行现金管理的核查意见